Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Medical Oncology

Managing Advanced and Metastatic Disease

At a Glance

Advanced or metastatic prostate cancer is managed with treatments that work throughout the body. The plan depends on whether the cancer is hormone-sensitive or castration-resistant, scan findings, genetic test results, prior treatments, and overall health.

Important: This page covers treatments for advanced prostate cancer. If your cancer is localized (confined to the prostate), the systemic treatments detailed here generally do not apply to your primary care plan.

When prostate cancer moves beyond the local area of the prostate or returns after initial treatment, the strategy shifts toward systemic therapies—treatments that work throughout your entire body. Modern imaging and a better understanding of the cancer’s “state” allow for highly personalized plans.

Finding the Cancer: The Role of PSMA PET/CT

For many years, doctors used “conventional imaging” like CT scans and bone scans to look for cancer. Today, PSMA PET/CT is increasingly considered or recommended for finding early recurrence or staging high-risk disease when the result will actually change management [1].

  • How it Works: This scan uses a radioactive tracer that attaches to PSMA (Prostate-Specific Membrane Antigen), a protein found in high amounts on the surface of most prostate cancer cells [2].
  • Precision: It is significantly more accurate than older scans at finding small amounts of cancer in the lymph nodes or bones [3].
  • Biochemical Recurrence: If your PSA begins to rise after surgery or radiation (known as biochemical recurrence), a PSMA PET/CT is often used to find exactly where the cancer is. It is not necessary for every patient, as PSMA expression can be heterogeneous, and false-positives can occur in benign bone lesions. Detection rates vary by tracer and prior treatment, but the scan is more likely to find cancer as the PSA level rises [4][5].

Stages of Advanced Disease

Advanced disease is broadly categorized, though these are not inevitable next steps for everyone:

  1. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): The cancer has spread, but it still responds to treatments that lower your testosterone [6].
  2. Castration-Resistant Prostate Cancer (CRPC): The cancer is growing despite testosterone being at very low (“castrate”) levels. In this stage, the cancer has found ways to grow without needing your body’s normal hormones. This can occur with or without metastasis [7][8].

Treatment for Hormone-Sensitive Disease (mHSPC)

The current standard of care is to use “upfront intensification.” Instead of using just one hormone therapy, doctors now use combinations:

  • Doublet Therapy: This is the most common approach, combining ADT (Androgen Deprivation Therapy) with an ARPI (Androgen Receptor Pathway Inhibitor) like abiraterone, enzalutamide, or apalutamide [6][9].
  • Triplet Therapy: For selected, sufficiently fit patients with “high-volume” disease (defined in the CHAARTED criteria as visceral metastases or 4 or more bone lesions with at least one beyond the pelvis and vertebral column), doctors may add a third treatment: Docetaxel chemotherapy [10][11]. This combination has been shown to help patients with aggressive, newly diagnosed metastatic cancer live longer [12]. In selected cases of low-volume de novo metastatic disease, prostate-directed radiation may also be considered.

Treatment for Castration-Resistant Disease (mCRPC)

If the cancer becomes resistant to standard hormone therapy, several targeted options are available:

  • PARP Inhibitors: If your tumor or germline testing shows specific genetic mutations (like BRCA1, BRCA2, or sometimes ATM), you may be eligible for drugs like olaparib or rucaparib. These drugs block a protein called PARP that cancer cells use to repair their DNA. Approvals differ by gene, germline vs tumor status, and prior AR-pathway exposure [13][14].
  • Radioligand Therapy (Lu-177 PSMA): Also known by the brand name Pluvicto, this is a “smart bomb” therapy. It uses the same PSMA target as the PET scan to deliver a dose of radiation directly to the cancer cells throughout the body [15]. While historically used after chemotherapy, specific jurisdictions now allow it for selected mCRPC patients after an AR-pathway inhibitor, delaying the need for taxane chemotherapy [16].
  • Next-Generation Chemotherapy: Drugs like cabazitaxel are used if the cancer progresses after docetaxel [17].

(Note: Treatment sequences change based on prior therapy and molecular results. Not every option applies to every patient.)

Protecting Your Bones

Prostate cancer frequently spreads to the bones, which can lead to pain or fractures. To prevent these “skeletal-related events,” doctors use high-dose bone-targeted agents like zoledronic acid (Zometa) or denosumab (Xgeva) specifically for patients with bone-metastatic castration-resistant disease [18].

  • Goal: These high-dose medications do not cure the cancer; they strengthen the bone to prevent breaks and reduce pain [19]. (This is distinct from lower-dose regimens used to prevent osteoporosis during standard ADT).
  • Important Precaution: These drugs carry a small risk of osteonecrosis of the jaw (ONJ), a condition where the jawbone does not heal properly [20]. It is highly recommended that you have a dental exam to reduce ONJ risk, but it should not unnecessarily delay urgent cancer care [21].
  • Calcium Monitoring: Because these drugs can lower your calcium levels, your doctor will monitor your kidney function and blood work, and likely recommend calcium and Vitamin D supplements tailored to your needs [22][23].

Common questions in this guide

How is hormone-sensitive metastatic prostate cancer different from castration-resistant disease?
A cancer is called metastatic hormone-sensitive prostate cancer when it has spread but still responds to treatments that lower testosterone. Castration-resistant prostate cancer is growing despite very low testosterone levels; it may occur with or without visible metastases.
What can a PSMA PET/CT show in advanced prostate cancer?
PSMA PET/CT uses a radioactive tracer that attaches to PSMA, a protein found on many prostate cancer cells. It can find small areas of cancer in lymph nodes or bones and help locate recurrence when PSA rises, but detection varies and benign lesions can sometimes look positive.
How is newly diagnosed metastatic hormone-sensitive prostate cancer treated?
Treatment usually combines androgen deprivation therapy with an androgen receptor pathway inhibitor such as abiraterone, enzalutamide, or apalutamide. Selected patients who are fit and have high-volume disease may also receive docetaxel, while prostate-directed radiation may be considered for some people with low-volume disease.
What treatments may be available when prostate cancer becomes castration-resistant?
Options depend on where the cancer is, genetic test results, previous medicines, and overall health. They may include PARP inhibitors for selected DNA-repair mutations, lutetium-177 PSMA radioligand therapy for eligible patients, and cabazitaxel after docetaxel.
Could genetic testing affect my prostate cancer treatment?
Testing the tumor or inherited DNA may identify mutations such as BRCA1, BRCA2, or ATM that can affect eligibility for a PARP inhibitor. Your oncology team can explain whether a result is inherited and how it may affect treatment decisions.
How can bone metastases and bone-protecting medicines be managed?
High-dose zoledronic acid or denosumab may be used for people with bone-metastatic castration-resistant prostate cancer to reduce fractures and other skeletal complications; these medicines do not cure the cancer. A dental examination, kidney and calcium monitoring, and individualized calcium and vitamin D advice can help manage risks such as jawbone injury and low calcium.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I in the 'hormone-sensitive' (mHSPC) or 'castration-resistant' (mCRPC) stage of the disease, and what does that mean for my immediate treatment options?
  2. 2.Based on my disease volume criteria, do you recommend a 'doublet' of ADT and a hormone pill, or a 'triplet' that includes docetaxel chemotherapy?
  3. 3.Has my tumor been tested for genetic mutations like BRCA2 or ATM, and if so, am I a candidate for a PARP inhibitor?
  4. 4.If we are using a PSMA PET/CT, are there any 'equivocal' spots that we should confirm with a biopsy or another type of scan?
  5. 5.Is Lu-177 (Pluvicto) an option for me now, and what are the specific eligibility requirements in our jurisdiction?
  6. 6.Before I start a high-dose bone-targeted agent like Xgeva or Zometa, do I need to see a dentist for any pending extractions or major work?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.

    Bennett R, Li EV, Ho AY, et al.

    The Prostate 2024; (84(8)):717-722 doi:10.1002/pros.24687.

    PMID: 38450787
  2. 2

    Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.

    Chow KM, So WZ, Lee HJ, et al.

    European urology 2023; (84(1)):36-48 doi:10.1016/j.eururo.2023.03.001.

    PMID: 37032189
  3. 3

    The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy.

    Soeterik TFW, Heetman JG, Hermsen R, et al.

    European urology oncology 2025; (8(3)):731-738 doi:10.1016/j.euo.2024.11.002.

    PMID: 39613565
  4. 4

    Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence.

    Seniaray N, Verma R, Khanna S, et al.

    Indian journal of urology : IJU : journal of the Urological Society of India 2020; (36(3)):191-199 doi:10.4103/iju.IJU_275_19.

    PMID: 33082634
  5. 5

    Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

    Perera M, Papa N, Roberts M, et al.

    European urology 2020; (77(4)):403-417 doi:10.1016/j.eururo.2019.01.049.

    PMID: 30773328
  6. 6

    Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.

    Azad AA, Kostos L, Agarwal N, et al.

    European urology 2025; (87(4)):455-467 doi:10.1016/j.eururo.2025.01.010.

    PMID: 39947976
  7. 7

    [Treatment algorithm following first-line therapy failure in metastatic prostate cancer].

    Thomas C, Merseburger AS

    Urologie (Heidelberg, Germany) 2025; (64(3)):229-236 doi:10.1007/s00120-024-02505-1.

    PMID: 39836209
  8. 8

    [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

    Hofman MS, Violet J, Hicks RJ, et al.

    The Lancet. Oncology 2018; (19(6)):825-833 doi:10.1016/S1470-2045(18)30198-0.

    PMID: 29752180
  9. 9

    Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.

    Sathianathen NJ, Koschel S, Thangasamy IA, et al.

    European urology 2020; (77(3)):365-372 doi:10.1016/j.eururo.2019.09.004.

    PMID: 31679970
  10. 10

    Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.

    Hussain M, Fizazi K, Shore ND, et al.

    JAMA oncology 2024; (10(6)):807-820 doi:10.1001/jamaoncol.2024.0591.

    PMID: 38722620
  11. 11

    Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.

    Fiorica F, Buttigliero C, Grigolato D, et al.

    Current oncology (Toronto, Ont.) 2022; (29(12)):9511-9524 doi:10.3390/curroncol29120747.

    PMID: 36547161
  12. 12

    Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

    Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, et al.

    Oncology reviews 2025; (19()):1599292 doi:10.3389/or.2025.1599292.

    PMID: 40787089
  13. 13

    Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review.

    Naqvi SAA, Anjum MU, Bibi A, et al.

    medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.04.15.25325837.

    PMID: 40321256
  14. 14

    First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.

    McKay RR, Morgans AK, Shore ND, et al.

    Cancer treatment reviews 2024; (126()):102726 doi:10.1016/j.ctrv.2024.102726.

    PMID: 38613872
  15. 15

    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Sartor O, de Bono J, Chi KN, et al.

    The New England journal of medicine 2021; (385(12)):1091-1103 doi:10.1056/NEJMoa2107322.

    PMID: 34161051
  16. 16

    Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

    Karimzadeh A, Lehnert W, Koehler D, et al.

    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2025; (197(9)):1033-1042 doi:10.1055/a-2514-4523.

    PMID: 39842443
  17. 17

    Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.

    Hatano K, Nonomura N

    The world journal of men's health 2023; (41(4)):769-784 doi:10.5534/wjmh.220200.

    PMID: 36792090
  18. 18

    Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

    Gartrell BA, Coleman R, Efstathiou E, et al.

    European urology 2015; (68(5)):850-8.

    PMID: 26153564
  19. 19

    Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.

    Jakob T, Tesfamariam YM, Macherey S, et al.

    The Cochrane database of systematic reviews 2020; (12()):CD013020 doi:10.1002/14651858.CD013020.pub2.

    PMID: 33270906
  20. 20

    Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool.

    Sahu KK, Johnson ED, Butler K, et al.

    Geriatrics (Basel, Switzerland) 2022; (7(6)) doi:10.3390/geriatrics7060133.

    PMID: 36547269
  21. 21

    Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

    Stopeck AT, Fizazi K, Body JJ, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(1)):447-455 doi:10.1007/s00520-015-2904-5.

    PMID: 26335402
  22. 22

    Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

    Body JJ, von Moos R, Niepel D, Tombal B

    BMC urology 2018; (18(1)):81 doi:10.1186/s12894-018-0393-9.

    PMID: 30236112
  23. 23

    Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

    Body JJ, Bone HG, de Boer RH, et al.

    European journal of cancer (Oxford, England : 1990) 2015; (51(13)):1812-21.

    PMID: 26093811

This page is for informational purposes only and does not constitute medical advice about advanced or metastatic prostate adenocarcinoma. Your oncology team can interpret your scans, genetic results, and treatment options for your specific situation.

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.